Search

Your search keyword '"Bonavita, Simona"' showing total 56 results
Start Over Author "Bonavita, Simona" Publisher elsevier bv
56 results on '"Bonavita, Simona"'

1. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

Author

Chisari, Clara G., primary, Aguglia, Umberto, additional, Amato, Maria Pia, additional, Bergamaschi, Roberto, additional, Bertolotto, Antonio, additional, Bonavita, Simona, additional, Morra, Vincenzo Brescia, additional, Cavalla, Paola, additional, Cocco, Eleonora, additional, Conte, Antonella, additional, Cottone, Salvatore, additional, De Luca, Giovanna, additional, Di Sapio, Alessia, additional, Filippi, Massimo, additional, Gallo, Antonio, additional, Gasperini, Claudio, additional, Granella, Franco, additional, Lus, Giacomo, additional, Maimone, Davide, additional, Maniscalco, Giorgia Teresa, additional, Marfia, Girolama, additional, Moiola, Lucia, additional, Paolicelli, Damiano, additional, Pesci, Ilaria, additional, Ragonese, Paolo, additional, Rovaris, Marco, additional, Salemi, Giuseppe, additional, Solaro, Claudio, additional, Totaro, Rocco, additional, Trojano, Maria, additional, Vianello, Marika, additional, Zaffaroni, Mauro, additional, Lepore, Vito, additional, Patti, Francesco, additional, Avolio, Carlo, additional, Balgera, Roberto, additional, Banfi, Paola, additional, Bellantonio, Paolo, additional, Bramanti, Placido, additional, Capone, Lorenzo, additional, Cavalletti, Guido, additional, Chiveri, Luca, additional, Clerici, Raffaella, additional, Clerico, Marinella, additional, Corea, Francesco, additional, Dattola, Vincenzo, additional, De Robertis, Francesca, additional, Di Battista, Giancarlo, additional, Galgani, Simonetta, additional, Gatto, Maurizia, additional, Grasso, Maria Grazia, additional, Inglese, Matilde, additional, Lo Russo, Lorenzo, additional, Logullo, Francesco Ottavio, additional, Mantegazza, Renato, additional, Protti, Alessandra, additional, Rezzonico, Monica, additional, Rottoli, Mariarosa, additional, Salvetti, Marco, additional, Scarpini, Elio, additional, Sinisi, Leonardo, additional, Sparaco, Maddalena, additional, Spitaleri, Daniele, additional, Tassinari, Tiziana, additional, Tonietti, Simone, additional, Valentino, Paola, additional, Valzania, Franco, additional, and Venturi, Simonetta, additional

Published
2024
Full Text
View/download PDF

2. Apparently isolated CNS involvement in Erdheim-Chester disease: Case report

Author

Romano, Giuseppe, primary, Cirillo, Mario, additional, Bonavita, Simona, additional, Toro, Giuseppe, additional, Di Pietro, Andrea, additional, Lavorgna, Luigi, additional, Maida, Elisabetta, additional, Pagliuca, Francesca, additional, Urraro, Fabrizio, additional, Coppola, Cinzia, additional, Lus, Giacomo, additional, and Signoriello, Elisabetta, additional

Published
2023
Full Text
View/download PDF

4. Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis

Author

Abbadessa, Gianmarco, primary, Ponzano, Marta, additional, Bile, Floriana, additional, Miele, Giuseppina, additional, Signori, Alessio, additional, Cepparulo, Simone, additional, Sparaco, Maddalena, additional, Signoriello, Elisabetta, additional, Maniscalco, Giorgia Teresa, additional, Lanzillo, Roberta, additional, Morra, Vincenzo Brescia, additional, Lus, Giacomo, additional, Sormani, Maria Pia, additional, Lavorgna, Luigi, additional, and Bonavita, Simona, additional

Published
2023
Full Text
View/download PDF

5. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

Author

Costabile, Teresa, primary, Signoriello, Elisabetta, additional, Lauro, Francesca, additional, Altieri, Manuela, additional, Ziello, Antonio Rosario, additional, D'Ambrosio, Alessandro, additional, Bisecco, Alvino, additional, Maniscalco, Giorgia, additional, Bonavita, Simona, additional, Gallo, Antonio, additional, Morra, Vincenzo Brescia, additional, Lus, Giacomo, additional, Saccà, Francesco, additional, and Russo, Cinzia Valeria, additional

Published
2023
Full Text
View/download PDF

6. Reduced Clinical Connectome Fingerprinting in Multiple Sclerosis Predicts Fatigue Severity

Author

Cipriano, Lorenzo, primary, Lopez, Emahnuel Troisi, additional, Liparoti, Marianna, additional, minino, roberta, additional, Romano, Antonella, additional, Polverino, Arianna, additional, Ciaramella, Francesco, additional, Ambrosanio, Michele, additional, Bonavita, Simona, additional, Jirsa, Viktor, additional, Sorrentino, Giuseppe, additional, and Sorrentino, Pierpaolo, additional

Published
2023
Full Text
View/download PDF

7. Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study

Author

Miele, Giuseppina, primary, Abbadessa, Gianmarco, additional, Cavalla, Paola, additional, Valentino, Paola, additional, Marfia, Girolama Alessandra, additional, Landi, Doriana, additional, Bosa, Chiara, additional, Vercellino, Marco, additional, De Martino, Antonio, additional, Ponzano, Marta, additional, Lavorgna, Luigi, additional, and Bonavita, Simona, additional

Published
2022
Full Text
View/download PDF

11. The progressive loss of brain network fingerprints in Amyotrophic Lateral Sclerosis predicts clinical impairment

Author

Romano, Antonella, primary, Trosi Lopez, Emahnuel, additional, Liparoti, Marianna, additional, Polverino, Arianna, additional, Minino, Roberta, additional, Trojsi, Francesca, additional, Bonavita, Simona, additional, Mandolesi, Laura, additional, Granata, Carmine, additional, Amico, Enrico, additional, Sorrentino, Giuseppe, additional, and Sorrentino, Pierpaolo, additional

Published
2022
Full Text
View/download PDF

12. Ocrelizumab treatment in multiple sclerosis: Prospective real world observational multi-center study in Campania, Italy

Author

Lanzillo, Roberta, primary, Carotenuto, Antonio, additional, Moccia, Marcello, additional, Capasso, Nicola, additional, Petracca, Maria, additional, Spiezia, Antonio, additional, Maniscalco, Giorgia, additional, Di Gregorio, Maria, additional, Sinisi, Leonardo, additional, Iodice, Rosa, additional, Dubbioso, Raffaele, additional, Bonavita, Simona, additional, Miele, Giuseppina, additional, Lus, Giacomo, additional, Signoriello, Elisabetta, additional, Mario, Fratta, additional, Bisecco, Alvino, additional, Felice, Romano, additional, Tedeschi, Gioacchino, additional, and Morra, Vincenzo Brescia, additional

Published
2021
Full Text
View/download PDF

17. Digital work engagement among Italian neurologists

Author

Brigo, Francesco, primary, Sormani, Mariapia, additional, Clerico, Marinella, additional, Ponzano, Marta, additional, Abbadessa, Gianmarco, additional, Cossu, Giovanni, additional, Trojsi, Francesca, additional, Colucci, Fabiana, additional, Tortorella, Carla, additional, Miele, Giuseppina, additional, Bozzali, Marco, additional, Sparaco, Maddalena, additional, Leocani, Letizia, additional, Lanzillo, Roberta, additional, Tedeschi, Gioacchino, additional, Bonavita, Simona, additional, and Lavorgna, Luigi, additional

Published
2021
Full Text
View/download PDF

18. Exit-strategies in Natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: A multicentre comparison study

Author

D'Amico, Emanuele, primary, Zanghì, Aurora, additional, Avolio, Carlo, additional, Gallo, Antonio, additional, Bonavita, Simona, additional, Lanzillo, Roberta, additional, Buccafusca, Maria, additional, Callari, Graziella, additional, Lus, Giacomo, additional, Sola, Patrizia, additional, Granella, Franco, additional, Valentino, Paola, additional, Mirabella, Massimilano, additional, and Patti, Francesco, additional

Published
2021
Full Text
View/download PDF

23. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Author

De Mercanti, Stefania Federica, primary, Signori, Alessio, additional, Cordioli, Cinzia, additional, Signoriello, Elisabetta, additional, Lus, Giacomo, additional, Bonavita, Simona, additional, Abbadessa, Gianmarco, additional, Lavorgna, Luigi, additional, Maniscalco, Giorgia Teresa, additional, Curti, Erica, additional, Lorefice, Lorena, additional, Cocco, Eleonora, additional, Nociti, Viviana, additional, Mirabella, Massimiliano, additional, Baroncini, Damiano, additional, Mataluni, Giorgia, additional, Landi, Doriana, additional, Petruzzo, Martina, additional, Lanzillo, Roberta, additional, Gandoglia, Ilaria, additional, Laroni, Alice, additional, Frangiamore, Rita, additional, Sartori, Arianna, additional, Cavalla, Paola, additional, Costantini, Gianfranco, additional, Capra, Ruggero, additional, Sormani, Maria Pia, additional, and Clerico, Marinella, additional

Published
2021
Full Text
View/download PDF

29. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

Author

Maniscalco, Giorgia T., primary, Saccà, Francesco, additional, Lanzillo, Roberta, additional, Annovazzi, Pietro, additional, Baroncini, Damiano, additional, Binello, Eleonora, additional, Repice, Annamaria, additional, Perini, Paola, additional, Clerico, Marinella, additional, Mataluni, Giorgia, additional, Bonavita, Simona, additional, La Gioia, Sara, additional, Gutierrez, Lorena Pareja, additional, Laroni, Alice, additional, Frau, Jessica, additional, Cocco, Eleonora, additional, Torri Clerici, Valentina, additional, Zarbo, Ignazio Roberto, additional, Sartori, Arianna, additional, Signoriello, Elisabetta, additional, Rasia, Sarah, additional, Cordioli, Cinzia, additional, Stromillo, Maria Laura, additional, Cerqua, Raffaella, additional, Pontecorvo, Simona, additional, Di Sapio, Alessia, additional, Grasso, Roberta, additional, Barone, Stefania, additional, Lavorgna, Luigi, additional, Barrilà, Caterina, additional, Landi, Doriana, additional, Russo, Cinzia Valeria, additional, Frigeni, Barbara, additional, Ippolito, Domenico, additional, Turano, Gabriella, additional, Carmisciano, Luca, additional, Sormani, Maria Pia, additional, and Signori, Alessio, additional

Published
2020
Full Text
View/download PDF

30. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Author

Clerico, Marinella, primary, De Mercanti, Stefania Federica, additional, Signori, Alessio, additional, Iudicello, Marco, additional, Cordioli, Cinzia, additional, Signoriello, Elisabetta, additional, Lus, Giacomo, additional, Bonavita, Simona, additional, Lavorgna, Luigi, additional, Maniscalco, Giorgia Teresa, additional, Curti, Erica, additional, Lorefice, Lorena, additional, Cocco, Eleonora, additional, Nociti, Viviana, additional, Mirabella, Massimiliano, additional, Baroncini, Damiano, additional, Mataluni, Giorgia, additional, Landi, Doriana, additional, Petruzzo, Martina, additional, Lanzillo, Roberta, additional, Gandoglia, Ilaria, additional, Laroni, Alice, additional, Frangiamore, Rita, additional, Sartori, Arianna, additional, Cavalla, Paola, additional, Costantini, Gianfranco, additional, Sormani, Maria Pia, additional, and Capra, Ruggero, additional

Published
2020
Full Text
View/download PDF

31. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

Author

Novi, Giovanni, primary, Bovis, Francesca, additional, Capobianco, Marco, additional, Frau, Jessica, additional, Mataluni, Giorgia, additional, Curti, Erica, additional, Zuliani, Luigi, additional, Cavalla, Paola, additional, Brambilla, Laura, additional, Annovazzi, Pietro, additional, Repice, Anna Maria, additional, Lanzillo, Roberta, additional, Esposito, Sabrina, additional, Benedetti, Luana, additional, Maietta, Ilaria, additional, Sica, Francesco, additional, Buttari, Fabio, additional, Malucchi, Simona, additional, Fenu, Giuseppe, additional, Landi, Doriana, additional, Bosa, Chiara, additional, Realmuto, Sabrina, additional, Malentacchi, Maria, additional, Granella, Franco, additional, Signori, Alessio, additional, Bonavita, Simona, additional, Uccelli, Antonio, additional, and Sormani, Maria Pia, additional

Published
2019
Full Text
View/download PDF

32. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod

Author

Vanoli, Emilio, primary, Montano, Nicola, additional, De Angelis, Giuseppe, additional, Badilini, Fabio, additional, Mirabella, Massimiliano, additional, Bonavita, Simona, additional, Patti, Francesco, additional, Bianco, Assunta, additional, Sparaco, Maddalena, additional, Chisari, Clara, additional, Laroni, Alice, additional, Frigerio, Francesca, additional, Bartezaghi, Marta, additional, Rossi, Silvia, additional, Turrini, Renato, additional, and Mancardi, Gianluigi, additional

Published
2019
Full Text
View/download PDF

39. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate

Author

Carrieri, Pietro B., primary, Carbone, Fortunata, additional, Perna, Francesco, additional, Bruzzese, Dario, additional, La Rocca, Claudia, additional, Galgani, Mario, additional, Montella, Silvana, additional, Petracca, Maria, additional, Florio, Ciro, additional, Maniscalco, Giorgia T., additional, Spitaleri, Daniele L.A., additional, Iuliano, Gerardo, additional, Tedeschi, Gioacchino, additional, Corte, Marida Della, additional, Bonavita, Simona, additional, and Matarese, Giuseppe, additional

Published
2015
Full Text
View/download PDF

40. Advantages of QBI in TBSS analyses

Author

Corbo, Daniele, primary, Caiazzo, Giuseppina, additional, Trojsi, Francesca, additional, Monsurrò, Maria Rosaria, additional, Gallo, Antonio, additional, Bonavita, Simona, additional, Tedeschi, Gioacchino, additional, and Esposito, Fabrizio, additional

Published
2014
Full Text
View/download PDF

42. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability

Author

Tedeschi, Gioacchino, primary, Dinacci, Daria, additional, Lavorgna, Luigi, additional, Prinster, Anna, additional, Savettieri, Giovanni, additional, Quattrone, Aldo, additional, Livrea, Paolo, additional, Messina, Corrado, additional, Reggio, Arturo, additional, Servillo, Giovanna, additional, Bresciamorra, Vincenzo, additional, Orefice, Giuseppe, additional, Paciello, Marcantonio, additional, Brunetti, Arturo, additional, Paolillo, Andrea, additional, Coniglio, Gabriella, additional, Bonavita, Simona, additional, Di Costanzo, Alfonso, additional, Bellacosa, Alessandra, additional, Valentino, Paola, additional, Quarantelli, Mario, additional, Patti, Francesco, additional, Salemi, Giuseppe, additional, Cammarata, Enrico, additional, Simone, Isabella, additional, Salvatore, Marco, additional, Bonavita, Vincenzo, additional, and Alfano, Bruno, additional

Published
2007
Full Text
View/download PDF

43. Lack of association between estrogen receptor 1 gene polymorphisms and multiple sclerosis in southern Italy in humans

Author

Savettieri, Giovanni, primary, Cittadella, Rita, additional, Valentino, Paola, additional, Manna, Ida, additional, Andreoli, Virginia, additional, La Russa, Antonella, additional, La Porta, Gaetana, additional, Ruscica, Francesca, additional, Ragonese, Paolo, additional, Pirritano, Domenico, additional, Bonavita, Simona, additional, Tedeschi, Gioacchino, additional, and Quattrone, Aldo, additional

Published
2002
Full Text
View/download PDF

45. Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study

Author

Giuseppina Miele, Gianmarco Abbadessa, Paola Cavalla, Paola Valentino, Girolama Alessandra Marfia, Doriana Landi, Chiara Bosa, Marco Vercellino, Antonio De Martino, Marta Ponzano, Luigi Lavorgna, Simona Bonavita, Miele, Giuseppina, Abbadessa, Gianmarco, Cavalla, Paola, Valentino, Paola, Marfia, Girolama Alessandra, Landi, Doriana, Bosa, Chiara, Vercellino, Marco, De Martino, Antonio, Ponzano, Marta, Lavorgna, Luigi, and Bonavita, Simona

Subjects
B cell, Vitamin D supplementation, Multiple Sclerosis, General Medicine, Vitamin D Deficiency, Settore MED/26, Neurology, Dietary Supplements, Multiple Sclerosi, Humans, Ocrelizumab, Neurology (clinical), Vitamin D, Retrospective Studies
Abstract

Background: Several observational studies have shown an association between low circulating levels of 25-hydroxy- vitamin D (25(OH)D) and an increase in inflammatory activity in Multiple Sclerosis (MS). Among its immunomodulatory functions, 25(OH)D suppresses proliferation and immunoglobulin production of B cells. 25(OH)D supplementation has been associated with better radiological outcomes in MS patients treated with interferon (IFN)-B, glatiramer acetate, fingolimod, natalizumab and rituximab. Our study is aimed at analyzing the association of 25(OH)D serum levels and supplementation with B cell kinetics and clinical-radiological outcomes of people with MS treated with ocrelizumab. Methods: We have retrospectively collected clinical and radiological data from 136 MS patients who have been treated with ocrelizumab, have undergone at least two treatment cycles and for whom data on serum 25(OH)D levels and intake were available. The patients were divided into three groups according to baseline 25(OH)D serum levels: deficient (≤19,9 ng/ml), insufficient (20-29,9 ng/ml), and normal range 25(OH)D (>30 ng/ml). According to 25(OH)D intake, we divided our population into users and non-users. To explore B cell kinetics at six- and twelve-month follow-ups, the patients were divided into two groups: with fast repopulation (FR) and slow repopulation rate (SR), based on the reappearance or non- appearance of CD19 at each time point. Results: When considering the entire population, the mean 25(OH)D serum level (sd) was 26.27 ng/ml (14.15). 43 (31,62%) patients were classified as deficient, 52 (38,24%) were classified as insufficient, and 41 (30,14%) showed 25(OH)D serum levels within the normal range. 60.29% (82/136) of the patients were classified as users, and 39.70% (54/136) as non-users. Over the eighteen-month treatment period, we observed a significant difference between the 25(OH)D users and the non-users as concerns the number of scans with at least one new/enlarging T2 lesion (2% vs 15.38%, respectively; p= 0.025). In the multinomial regression model, 25(OH)D deficiency (serum levels ≤19,9 ng/ml) was significantly associated with a higher likelihood of disease activity during a follow-up of eighteen months (p=0.029, RRR=4.84, Confidence Interval (CI) 1.17 - 20.01). After six months, there were 30/136 FR patients (22,05%), whereas only 22/136 (16,17%) showed early B cell reappearance at twelve month follow up. 86.66% of the patients in the FR group showed 25(OH)D levels lower than 30 ng/ml (25(OH)D deficiency or insufficiency), whereas only 65.09% of the SR patients presented vitamin D levels lower than 30 ng/ml (p= 0.024). In the logistic regression model, 25(OH)D serum levels below 30 ng/ml were associated with a higher likelihood of early B cell reappearance at six month follow up (p= 0.042). Conclusions: 25(OH)D supplementation and serum levels might be associated with B cell kinetics and radiological activity of patients with MS treated with ocrelizumab.

Published
2022

46. Screening neuromyelitis optica patients for COVID-19 infection

Author

Saeed Vaheb, Mahdi Barzegar, Omid Mirmosayyeb, Vahid Shaygannejad, Mahsa Ghajarzadeh, Simona Bonavita, Mirmosayyeb, Omid, Vaheb, Saeed, Barzegar, Mahdi, Shaygannejad, Vahid, Bonavita, Simona, and Ghajarzadeh, Mahsa

Subjects
2019-20 coronavirus outbreak, Neuromyelitis optica, Coronavirus disease 2019 (COVID-19), biology, business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Neuromyelitis Optica, Pneumonia, Viral, Immunology, COVID-19, medicine.disease, biology.organism_classification, Virology, Article, Betacoronavirus, Pandemic, Medicine, Humans, Immunology and Allergy, business, Coronavirus Infections, Pandemics
Published
2020
Full Text
View/download PDF

47. Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis

Author

Sabrina Esposito, Alvino Bisecco, Maddalena Sparaco, Antonio Gallo, Luigi Lavorgna, Robert W. Motl, Simona Bonavita, Gioacchino Tedeschi, Lavorgna, Luigi, Sparaco, Maddalena, Esposito, Sabrina, Motl, Robert W., Gallo, Antonio, Bisecco, Alvino, Tedeschi, Gioacchino, and Bonavita, Simona

Subjects
Adult, Male, medicine.medical_specialty, Validation study, Multiple Sclerosis, Walking, Disability Evaluation, 03 medical and health sciences, 0302 clinical medicine, Physical medicine and rehabilitation, Humans, Medicine, Patient Reported Outcome Measures, 030212 general & internal medicine, Reproducibility, business.industry, Multiple sclerosis, Reproducibility of Results, General Medicine, Middle Aged, Translating, medicine.disease, Neurology, DISEASE STEPS, Scale (social sciences), Exercise Test, Physical therapy, Regression Analysis, Female, Neurology (clinical), business, 030217 neurology & neurosurgery
Published
2017

48. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Author

Doriana Landi, Gianmarco Abbadessa, Gianfranco Costantini, Giacomo Lus, Stefania Federica De Mercanti, Cinzia Cordioli, Simona Bonavita, Giorgia Mataluni, Massimiliano Mirabella, Maria Pia Sormani, Ilaria Gandoglia, Giorgia Teresa Maniscalco, Martina Petruzzo, Rita Frangiamore, Eleonora Cocco, Erica Curti, Damiano Baroncini, Ruggero Capra, Elisabetta Signoriello, Paola Cavalla, Luigi Lavorgna, Lorena Lorefice, Alice Laroni, Marinella Clerico, Viviana Nociti, Alessio Signori, Arianna Sartori, Roberta Lanzillo, De Mercanti, Stefania Federica, Signori, Alessio, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Abbadessa, Gianmarco, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Capra, Ruggero, Sormani, Maria Pia, Clerico, Marinella, De Mercanti, S. F., Signori, A., Cordioli, C., Signoriello, E., Lus, G., Bonavita, S., Abbadessa, G., Lavorgna, L., Maniscalco, G. T., Curti, E., Lorefice, L., Cocco, E., Nociti, V., Mirabella, M., Baroncini, D., Mataluni, G., Landi, D., Petruzzo, M., Lanzillo, R., Gandoglia, I., Laroni, A., Frangiamore, R., Sartori, A., Cavalla, P., Costantini, G., Capra, R., Sormani, M. P., and Clerico, M.

Subjects
medicine.medical_specialty, Efficacy, Progressive Multifocal, Relapsing-Remitting, Settore MED/26, law.invention, Multiple sclerosis, 03 medical and health sciences, Magnetic resonance imaging, Immunologic Factor, Multiple Sclerosis, Relapsing-Remitting, 0302 clinical medicine, Natalizumab, Randomized controlled trial, Leukoencephalopathy, Retrospective Studie, law, Internal medicine, Multiple Sclerosi, Humans, Immunologic Factors, Medicine, 030212 general & internal medicine, Dosing, Retrospective Studies, Extended dose, medicine.diagnostic_test, business.industry, Progressive multifocal leukoencephalopathy, Leukoencephalopathy, Progressive Multifocal, Retrospective cohort study, medicine.disease, Settore MED/26 - NEUROLOGIA, Regimen, Italy, Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurology (clinical), business, 030217 neurology & neurosurgery, Human, medicine.drug
Abstract

Background: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID). Methods: Observational, multicentre, retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Three hundred and sixteen patients were enrolled. The median dose interval (MDI) following the 24th infusion was 5 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Patients were grouped into 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Results: One hundred and eighty-seven patients were in the SID group (MDI = 4.5 weeks) and 129 in the EID group (MDI 6.1 weeks). The risk to develop active lesions on MRI is similar in SID and EID groups during the 6 and 12 months after the 24th natalizumab infusion, respectively 4.27% (95% CI:0.84–7.70) vs 4.71% (95% CI:0.16–9.25%) [p = 0.89] and 8.50% (95% CI:4.05–12.95) vs 6.55% (95% CI:2.11–11.00%) [p = 0.56]. The EID regimen does not appear to increase the occurrence of MRI activity during follow-up. Conclusion: There is no evidence of the reduced efficacy of natalizumab in an EID setting regarding the MRI activity. This observation supports the need for a bigger randomized study to assess the need to change the standard of the natalizumab dosing schedule, to better manage JCV-positive patients.

Published
2021

49. The role of sex hormones in women with multiple sclerosis: From puberty to assisted reproductive techniques

Author

Maddalena Sparaco, Simona Bonavita, Sparaco, Maddalena, and Bonavita, Simona

Subjects
0301 basic medicine, Multiple Sclerosis, Reproductive Techniques, Assisted, medicine.drug_class, Oral contraceptive, Physiology, 03 medical and health sciences, 0302 clinical medicine, Immune system, Pregnancy, medicine, Humans, Multiple sclerosi, Gonadal Steroid Hormones, Autoimmune disease, Reproductive Technique, Endocrine and Autonomic Systems, business.industry, Multiple sclerosis, Puberty, Assisted reproductive technique, medicine.disease, Estrogen, Menopause, 030104 developmental biology, Female, business, 030217 neurology & neurosurgery, Hormone
Abstract

Background Multiple Sclerosis is a multifactorial chronic autoimmune disease, affecting predominantly females in the fertile age. Sex hormones changes during a woman's life, from puberty to menopause, including pregnancy and puerperium, may influence the onset and course of Multiple Sclerosis. The effect of estrogen levels on immune, clinical and radiological aspects of Multiple Sclerosis, also stimulated investigation on the effect of sexual hormones therapies, such as oral contraceptives and assisted reproductive technique, on the Multiple Sclerosis course. Search strategy and selection criteria A literature search for original articles and reviews was conducted in the databases, including PubMed, Scopus, and ClinicalTrials.gov of the U.S. National Library of Medicine site from 1988 to 2020. Results and conclusion This review reports the effects of the physiological and iatrogenic hormonal changes either on immune or clinical or paraclinical features in the different life stages of women affected by Multiple Sclerosis.

Published
2021

50. The Dress: Transforming a web viral event into a scientific survey

Author

Gioacchino Tedeschi, Simona Bonavita, Roberta Lanzillo, Vincenzo Brescia Morra, Luigi Lavorgna, Marcello Moccia, Moccia, Marcello, Lavorgna, Luigi, Lanzillo, Roberta, Brescia Morra, Vincenzo, Tedeschi, Gioacchino, Bonavita, Simona, and BRESCIA MORRA, Vincenzo

Subjects
Adult, Male, Research design, Aging, Multiple Sclerosis, Time Factors, Adolescent, genetic structures, Demographics, Color vision, media_common.quotation_subject, Population, Color, 050105 experimental psychology, Clothing, Social Networking, Young Adult, 03 medical and health sciences, Social, 0302 clinical medicine, Negatively associated, Surveys and Questionnaires, Perception, Humans, Multiple sclerosi, 0501 psychology and cognitive sciences, Young adult, education, Aged, media_common, Internet, education.field_of_study, White (horse), 05 social sciences, General Medicine, The dre, Middle Aged, Neurology, Research Design, Disease Progression, Female, Neurology (clinical), Psychology, Social psychology, Color Perception, Photic Stimulation, psychological phenomena and processes, 030217 neurology & neurosurgery, Clinical psychology
Abstract

Background The Dress picture recently has become a hot topic on the Internet, prompting a debate whether it was black and blue, or white and gold. Objective To investigate The Dress color perception in both multiple sclerosis (MS) patients, characterized by frequent visual system impairment with ensuing color vision effects, and general population. Methods We developed a questionnaire to record demographics, clinical features, and The Dress color perception, posted on general and MS-specific social networks. Results No statistically significant differences were observed in The Dress color perception between MS patients ( n =103) and general population ( n =441). Furthermore, white and gold color perception was positively associated with aging in the general population ( p =0.04), whereas negatively associated with progressive course ( p =0.03) and longer disease duration ( p Conclusion The Dress black and blue or white and gold perception might be due to aging in the general population, whereas black and blue perception, despite of aging, might suggest a specific effect of the MS burden (i.e. disease duration and progression) on the visual structures specifically involved in the white and gold perception.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results